DLL3
Delta-like protein 3
As of the edition of 20 October 2026, DLL3 (delta-like protein 3, UniProt Q9NYJ7) has 4 drugs tested at it and 6 companies on the list, 2 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9NYJ7
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Disease areas
- Cancer; Lungs and airways; Chemically induced; Injuries; Nervous system; Skin and connective tissue; Urinary and reproductive; Hormones
- Registered trials of its drugs
- 58
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tarlatamab | Marketed | Phase 3 | Ends 2036 |
| Rovalpituzumab tesirine | Stopped | Phase 3 | none listed |
| ZL-1310 | Active | Phase 3 | none listed |
| IBI3009 | Active | Phase 1 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 2 |
| Route B | 1 |
| Engaged | 3 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| AbbVie | Route A |
| Amgen | Route B |
| Stemcentrx | Route A |
The other 3 companies at DLL3
In the product6 companies in all; 3 are not named here, and no score is.
See the 6 companies at DLL3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.